Targeting the host to control an infection disorder

Archives of Internal Medicine

Volumn 168, Issue 19, 2008, Pages 2067-2068

  Haldar, Kasturi ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CHOLESTEROL; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BACTERIAL INFECTION; CHOLESTEROL SYNTHESIS; DRUG MECHANISM; EDITORIAL; HOST; HUMAN; INFECTION CONTROL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PNEUMONIA;

EID: 54949094706     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.19.2067     Document Type: Editorial

References (20)

1. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988; 62(15):10J-15J.
2. Angelin B. Regulation of hepatic cholesterol metabolism in man. Ann Med. 1991; 23(2):177-180.
3. Hennekens CH. Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease. Clin Cardiol. 2001;24(suppl):II-2-II-5.
4. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37.
5. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sørensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29 900 patients. Arch Intern Med. 2008; 168(19):2081-2087.
6. Lange Y, Steck TL. The role of intracellular cholesterol transport in cholesterol homeostasis. Trends Cell Biol. 1996;6(6):205-208.
7. Loike JD, Shabtai DY, Neuhut R, et al. Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler Thromb Vasc Biol. 2004;24(11):2051-2056.
8. Kay JG, Murray RZ, Pagan JK, Stow JL. Cytokine secretion via cholesterol-rich lipid raft-associated SNAREs at the phagocytic cup. J Biol Chem. 2006;281 (17):11949-11954.
9. McTaggart SJ. Isoprenylated proteins. Cell Mol Life Sci. 2006;63(3):255-267.
10. ten Klooster JP, Hordijk PL. Targeting and localized signalling by small GTPases. Biol Cell. 2007;99(1):1-12.
11. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays. 2007;29(4):356-370.
12. Montaner S, Perona R, Saniger L, Lacal JC. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J Biol Chem. 1998;273(21):12779-12785.
13. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem. 2007;282(37):26832-26844.
14. Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Curr Cancer Drug Targets. 2006;6(1):15-37.
15. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov. 2007;6(7):541-555.
16. Aepfelbacher M, Trasak C, Ruckdeschel K. Effector functions of pathogenic Yersinia species. Thromb Haemost. 2007;98(3):521-529.
17. Burnham CA, Shokoples SE, Tyrrell GJ. Rac1, RhoA, and Cdc42 participate in HeLa cell invasion by group B streptococcus. FEMS Microbiol Lett. 2007;272 (1):8-14.
18. Catron DM, Lange Y, Borensztajn J, Sylvester MD, Jones BD, Haldar K. Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway. Infect Immun. 2004;72(2):1036-1042.
19. Chua D, Tsang RS, Kuo IF. The role of statin therapy in sepsis. Ann Pharmacother. 2007;41(4):647-652.
20. Dunn SE, Youssef S, Goldstein MJ, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006;203(2):401-412.